Long-Overdue Guidelines for the Cord Blood Banking Community

HAL E. BROXMEYER

Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence: Hal E. Broxmeyer, Ph.D., Indiana University School of Medicine, Department of Microbiology and Immunology, 950 West Walnut Street, Bldg. R2, Room 302, Indianapolis, Indiana 46202, USA. Telephone: 317-274-7510; Fax: 317-274-7372; E-mail: hbroxmeyer@iupui.edu

A Commentary on the Cord Blood Model Criteria Guidelines in this issue.

Received February 27, 2019; accepted for publication February 27, 2019; first published March 7, 2019.

http://dx.doi.org/10.1002/sctm.19-0056

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The article entitled “Model Criteria for Regulation of Cord Blood Banks and Cord Blood Banking” [1] is a concise set of recommendations for the field of hematopoietic cell transplantation (HCT). Specifically, it relates to the field of cord blood (CB) transplantation. It was put together by members of the Government and Global Affairs Committee of the Cord Blood Association (CBA), who represent 15 different countries, and was adopted by the Board of Directors of the CBA on January 29, 2019. This is a long-overdue set of guidelines for the international and national communities and offers criteria for quality management, consent and contract with the family for private banking, donor screening and testing, collection procedures for CB units, manufacturing effects, potency of units and release of the CB units for transplantation, shipping and transplantation, monitoring of outcomes, registry participation and the sharing of data, and laboratory testing. These are noteworthy guidelines that help clarify present needs. The guidelines will likely be modified in time, as this model is adopted and other criteria for use of this life-saving procedure are used throughout the world. It is not a surprise that these model guidelines have been provided by an international group of investigators. While the biology and science of CB hematopoietic stem (HSC) and progenitor (HPC) cells that led to the first and subsequent CB HCTs was a national effort [2], the actual clinical use of these CB units for HCT was an international affair [3] that has been followed by well over 40,000 CB transplants that have been used to treat a large variety of malignant and non-malignant disorders that were previously treated by bone marrow (BM) HCT and that are now are being treated also by CB, BM, and cytokine-induced mobilized peripheral blood (mPB) HCT.

CB HCT has advantages and disadvantages as a source of donor cells, compared with BM- and mPB-HCT, which have been highlighted in numerous review articles, including those on behalf of my institution [4–6]. At this point in time, it is crucial for the field of CB HCT to not only set international guidelines for the use of CB HSC and HPC for HCT, but to move forward with enhancing the efficacy of CB HSC and HPC for more favorable results. This encompasses consistently using single CB units for transplantation and substantially decreasing the time to neutrophil, platelet, and immune cell recovery, which is presently substantially slower than that for BM, and especially for mPB HCT even with very much improved clinical care of patients undergoing CB HCT [6]. Efforts in these directions include the collection of increased numbers of HSC for banked CB units, the expansion of CB HSC ex-vivo, and enhancing the homing efficiency of the CB HSC so that they efficiently reach the host BM microenvironment where they can be nurtured for survival, proliferation, self-renewal, and appropriate differentiation. All these efforts are ongoing by many groups nationally and internationally and have been noted in several of review articles [4–6]. However, a major concern for clinical improvements in the field of CB HCT, which needs serious addressing, is that most of these efforts have not yet been adapted for clinical trials to test their efficacy of action. It is imperative that a way be found, and soon, to bring many of these interesting procedures for testing in a clinical situation; some may be useful, while others may not translate efficiently for clinical advantage. These procedures need to be readily adaptable for CB HCT, which means that the simpler the procedure, the better. They must also be cost effective, without addition of very high additional costs, unless the additional costs can be justified in terms of short- and long-term clinical effectiveness [7].

Preclinical and clinical efforts by my group, with regard to experimental strategies to improve clinical CB HCT, are diagrammed in Figure 1. This includes the collection of increasing numbers of HSC in CB units through the collection and processing of the cells in a hypoxic atmosphere of 3% O₂, while the cells are never subjected to ambient air (~21% O₂) [8]. While this procedure routinely allows collection of two- to fivefold more phenotypically and functionally (engrafting) HSC than that seen with the routine collection of such cells in ambient air, it is clearly not feasible to adapt such collection/processing
methods for routine use. Hence efforts are being investigated
to collect CB in ambient air but in the presence of cyclosporine
A or combinations of antioxidant(s) plus/minus epigenetic enzyme inhibitor(s), which mimic to a degree the collection/processing
of cells in hypoxia [8, 9]. There is also a means to increase
numbers of already collected CB HSCs by expansion. In this
context, we have looked at adding either inhibitors of dipepti-
dylpeptidase (DPP)4 [10, 11], enhancing expression of Oct4
[12], using antagonists of peroxisome proliferator-activated
receptor (PPAR-γ) [13], or adding the heterochromatin remo-
deling nuclear protein DEK [14]. DEK acts in this effect through
a cytokine-mediated CXCR2 chemokine receptor-signaling path-
way, rather than through the remodeling of nuclear heterochro-
matin [14]. Ongoing efforts in this also include modulating CD166
expression [J. Zhang, C. Zhang, X. Huang et al., manuscript sub-
mitted for publication]. We have also investigated agents to en-
hance the homing capabilities of CB HSC. This includes the roles of
glucocorticosteroids [15], inhibitors of histone deacetylase
(HDAC) 5 [16], inhibitors of DPP4 in vitro [10, 11] and in vivo in
patients using the FDA-approved orally active DPP4-inhibitor sita-
gliptin [17], combinations of a DPP4 inhibitor plus prostaglandin
(PGE) [18], and short-term exposure of cells to mild heat (39°C)
exposure [19]. Treatment of recipients undergoing CB HCT has
also used hyperbaric chambers [20]. All of the above-described
laboratory/clinical procedures, as well as those noted in my
reviews [4–6], can be used alone to enhance preclinical/clinical
CB HCT of human cells, but there is no reason that they cannot
also be used in combination in sequence as noted in Figure 1,
efforts currently ongoing in the laboratory, to see if such sequen-
tial combinations can more effectively enhance the ef-
cacy of the CB cells for HCT than each single procedure. Regardless of
the preclinical outcomes, it is crucial that a way be found to
investigate these efforts for clinical translation. This is not an easy
undertaking, because there are just so many transplant centers
doing CB HCT, and most centers have their favorite efforts, which
leaves little time or desire to pursue other areas. This will likely
require international CB HCT collaborative efforts, such as that
which helped start the field of CB HCT [3].

These additional efforts, if successful in a clinical setting,
will no doubt require additional modifications to the suggested
model criteria [1]. All in the field of lab-based scientific and
clinical efforts for enhanced CB HCT look forward to these
clinical translations of ongoing lab and preclinical work and will gladly welcome further modifications to the present proposed guidelines, as necessary.

**ACKNOWLEDGMENTS**

Works referenced in this commentary that were performed on behalf of the author’s laboratory were supported by the following Public Health Service Grants from the NIH: R01 DK109188, U54 DK106846, R01 HL056416, R01 HL112669, R35 HL139599, T32 DK007519, and T32 HL007910. The author is a member of the Cord Blood Association, which presented the article entitled “Model Criteria for Cord Blood Banks and Cord Blood Banking”; however, he was not involved in the development of the Model Criteria.

**DISCLOSURES**

The author indicated no potential conflicts of interest.

**REFERENCES**

1. Cord Blood Association. Model Criteria for Cord Blood Banks and Cord Blood Banking. *Stem Cells Translational Medicine* 2019;8:340–343.
2. Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828–3832.
3. Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174–1178.
4. Broxmeyer HE, Farag SS, Rocha V. Cord Blood Hematopoietic Cell Transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 1, 5th ed. Oxford, England: John Wiley & Sons, Ltd., 2016:Chapter 39:437–455.
5. Broxmeyer HE. The history of cord blood transplantation/biology and perspective for future efforts to enhance the field. Cell Gene Therapy Insights 2017;3:521–530.
6. Broxmeyer HE, Milano F. Cord Blood Transplantation: State of the Science. Cord Blood Association (CBA). Available at https://www.cb-association.org/state-of-the-science. Accessed March 2018.
7. Broxmeyer HE, Farag S. Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns. Stem Cells Dev 2013;22(suppl 1):103–110.
8. Mantel CR, O’Leary HA, Chitteti BR et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell 2015;161:1553–1565.
9. Cai Q, Capitano M, Huang X et al. Combinations of antioxidants and/or of epigenetic enzyme inhibitors allow for enhanced collection of mouse bone marrow hematopoietic stem cells in ambient air. Blood Cells Mol Dis 2018;71:23–28.
10. Christopherson KW 2nd, Hangoc G, Mantel CR et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004;305:1000–1003.
11. Broxmeyer HE, Hoggatt J, O’Leary HA et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012;18:1786–1796.
12. Huang X, Lee MR, Cooper S et al. Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression. Leukemia 2016;30:144–153.
13. Guo B, Huang X, Lee MR et al. Antagonism of PPAR-γ signaling expands human hematopoietic stem and progenitor cells by enhancing glycolysis. Nat Med 2018;24:360–367.
14. Capitano ML, Mor-Vaknin N, Saha AK et al. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling. J Clin Invest 2018; (in press).
15. Guo B, Huang X, Cooper S et al. Glucocorticoid hormone-induced chromatin remodeling enhances human hematopoietic stem cell homing and engraftment. Nat Med 2017;23:424–428.
16. Huang X, Guo B, Liu S et al. Neutralizing negative epigenetic regulation by HDAC5 enhances human hematopoietic stem cell homing and engraftment. Nat Commun 2018;9:2741.
17. Farag SS, Nelson R, Cairo MS et al. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. Oncotarget 2017;8:110350–110357.
18. Broxmeyer HE, Pelus LM. Inhibition of DPP4/CD26 and dmPGE(2) treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 2014;53:34–38.
19. Capitano ML, Hangoc G, Cooper S et al. Mild heat treatment primes human CD34+ cord blood cells for migration toward SDF-1α and enhances engraftment in an NSG mouse model. *Stem Cells* 2015;33:1975–1984.
20. Aljitawi OS, Paul S, Ganguly A et al. Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation. Blood 2016;128:3000–3010.